Literature DB >> 12066193

Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.

Robert L Zimmerman1, Franz Fogt, Melissa Burke, Linda A Murakata.   

Abstract

Hepatocellular carcinoma (HCC), cholangiocarcinoma (Chca) and benign bile ductule proliferations represent uncommon but important differential diagnoses in liver masses, especially if the patient has no known primary malignancy. The glucose transporter protein Glut-1 is commonly expressed in adenocarcinomas but its expression in HCC, Chca, and benign bile ductules has not been systematically investigated. Forty-two cases of Chca, 27 cases of benign bile ductule proliferations and 19 cases of HCC were stained with Glut-1. Cases were evaluated for a membranous staining pattern in tumor cells and the results compared. Twenty-one of 42 (50%) Chca stained with Glut-1 while no HCC or benign bile ductule proliferations did, neither did benign hepatocytes or portal triad structures. Glut-1 is a highly specific but insensitive stain for Chca. It may prove to be a helpful part of a diagnostic panel used to evaluate liver lesions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12066193

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  10 in total

1.  GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.

Authors:  Thomas Amann; Ulrike Maegdefrau; Arndt Hartmann; Abbas Agaimy; Jörg Marienhagen; Thomas S Weiss; Oliver Stoeltzing; Christina Warnecke; Jürgen Schölmerich; Peter J Oefner; Marina Kreutz; Anja K Bosserhoff; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

2.  Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma.

Authors:  Katjana Daskalow; David Pfander; Wilko Weichert; Nadine Rohwer; Armin Thelen; Peter Neuhaus; Sven Jonas; Bertram Wiedenmann; Christoph Benckert; Thorsten Cramer
Journal:  Histochem Cell Biol       Date:  2009-04-07       Impact factor: 4.304

3.  Dysregulated hepatic expression of glucose transporters in chronic disease: contribution of semicarbazide-sensitive amine oxidase to hepatic glucose uptake.

Authors:  Sumera Karim; Evaggelia Liaskou; Janine Fear; Abhilok Garg; Gary Reynolds; Lee Claridge; David H Adams; Philip N Newsome; Patricia F Lalor
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-10-23       Impact factor: 4.052

Review 4.  Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease.

Authors:  Alexandra Chadt; Hadi Al-Hasani
Journal:  Pflugers Arch       Date:  2020-06-26       Impact factor: 3.657

5.  Dysregulation of the miR-148a-GLUT1 axis promotes the progression and chemoresistance of human intrahepatic cholangiocarcinoma.

Authors:  Pei Tiemin; Xiao Peng; Lang Qingfu; Wang Yan; Xue Junlin; He Zhefeng; Zhao Ming; Liang Desen; Meng Qinghui
Journal:  Oncogenesis       Date:  2020-02-13       Impact factor: 7.485

6.  Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [18F]F-FDG PET/CT in Patients with Liver Malignancies.

Authors:  Dheeratama Siripongsatian; Chetsadaporn Promteangtrong; Anchisa Kunawudhi; Peerapon Kiatkittikul; Natphimol Boonkawin; Chatchawarin Chinnanthachai; Attapon Jantarato; Chanisa Chotipanich
Journal:  Mol Imaging Biol       Date:  2022-04-29       Impact factor: 3.484

Review 7.  FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background.

Authors:  Kumi Ozaki; Kenichi Harada; Noboru Terayama; Nobuyuki Kosaka; Hirohiko Kimura; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2020-04-03       Impact factor: 2.374

Review 8.  Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor.

Authors:  Masakatsu Tsurusaki; Masahiko Okada; Hiroyuki Kuroda; Mitsuru Matsuki; Kazunari Ishii; Takamichi Murakami
Journal:  J Gastroenterol       Date:  2013-03-26       Impact factor: 7.527

9.  Quantitative assessment of simultaneous F-18 FDG PET/MRI in patients with various types of hepatic tumors: Correlation between glucose metabolism and apparent diffusion coefficient.

Authors:  Eunjung Kong; Kyung Ah Chun; Ihn Ho Cho
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

10.  Glucose Transporter-1 (GLUT-1) Expression is Associated with Tumor Size and Poor Prognosis in Locally Advanced Gastric Cancer.

Authors:  Chenqing Yin; Bin Gao; Ju Yang; Jingbo Wu
Journal:  Med Sci Monit Basic Res       Date:  2020-03-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.